Science Explorer Back to mapMap

Most cited papers from Bexion Pharmaceuticals (United States)

What are the most cited papers from Bexion Pharmaceuticals (United States)?

The most cited paper from Bexion Pharmaceuticals (United States) is "Prevalence of Helicobacter Pylori in Asymptomatic Population a Pilot Serological Study in Bangladesh" (Mian Mashhud Ahmad, Mahbubur Rahman, Azharul Karim Rumi et al., 1997), with 89 citations. Next come "Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine" (18) and "Model nematodes as a practical innovation to promote high throughput screening of natural products for anthelmintics discovery in South Asia: Current challenges, proposed practical and conceptual solutions" (8).

Showing 15 of 15 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Prevalence of Helicobacter Pylori in Asymptomatic Population a Pilot Serological Study in Bangladesh Mian Mashhud Ahmad, Mahbubur Rahman, Azharul Karim Rumi et al. · Journal of Epidemiology Open access 1997 89
2 Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine Patrick M. Winter, John Pearce, Zhengtao Chu et al. · Journal of Magnetic Resonance Imaging Open access 6 May 2014 18
3 Model nematodes as a practical innovation to promote high throughput screening of natural products for anthelmintics discovery in South Asia: Current challenges, proposed practical and conceptual solutions Muntasir Kamal, Suprabhat Mukherjee, Bishnu P. Joshi et al. · Molecular and Biochemical Parasitology 18 Sep 2023 8
4 An Assessment to Identify Causes of ERP Implementation Failure and to Predict Its Success: A Case Study on Beximco Pharmaceuticals Limited Mohammad Anisur Rahman, Bijeta Saha · SSRN Electronic Journal PreprintOpen access 2016 6
5 A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas Olivier Rixe, John Lee Villano, Robert Wesolowski et al. · Clinical Cancer Research Open access 12 Sep 2024 5
6 An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors Mohamed Shebl Abdelbaki, Mariko Dawn DeWire Schottmiller, Timothy P. Cripe et al. · Heliyon Open access Dec 2022 4
7 Investigation of In-vitro Antioxidant and Cytotoxic Activity of Blumea lacera (Burm.f.) DC. Leaf Chloroform Extract Mujtaba Ali Khan, Sanjoy Kumer Paul · Current Perspectives on Medicinal and Aromatic Plants (CUPMAP) Open access 25 Nov 2025 0
8 A phase 1 study to evaluate the safety and tolerability of BXQ-350, a novel sphingolipid metabolism modulator, in pediatric diffuse intrinsic pontine glioma and diffuse midline glioma. Tariq Arshad, Michael Gazda, Jim Beach et al. · Journal of Clinical Oncology Open access 28 May 2025 0
9 Effect of BXQ-350, a novel sphingolipid metabolism modulator, on neuronal environments through modulation of gene pathways. Michael Gazda, Tariq Arshad, Jim Beach et al. · Journal of Clinical Oncology 28 May 2025 0
10 Development and Validation of Uv-Vis Spectroscopic Method for the Determination of Anticancer Drug Brigatinib Mossammat Rima Akter, Md. Saddam Hossain, Shomrat Saikh - et al. · SSRN Electronic Journal PreprintOpen access 2023 0
11 Model Nematodes as a Practical Innovation to Promote High Throughput Screening of Natural Products for Anthelmintics Discovery in South Asia: Current Challenges, Proposed Practical & Conceptual Solutions Muntasir Kamal, Suprabhat Mukherjee, Bishnu P. Joshi et al. · SSRN Electronic Journal PreprintOpen access 2023 0
12 Title: Phase 1 Safety Study of BXQ-350 in Children/Young Adults with Relapsed Solid Tumors, Including Malignant Brain Tumors Mohamed Shebl Abdelbaki, Mariko Dawn DeWire Schottmiller, Timothy P. Cripe et al. · SSRN Electronic Journal PreprintOpen access 2022 0
13 Evaluation of outcome of Coronavirus disease 2019 patients receiving RAAS inhibitors (OCRAS study): a prospective observational study of Bangladeshi hypertensive patients Arman Majumder, Mahamudur Rahman, A K M Monwarul Islam et al. · European Heart Journal Open access Feb 2022 0
14 CTNI-78. A PEDIATRIC AND YOUNG ADULT PHASE I DOSE ESCALATION SAFETY STUDY OF BXQ-350 FOR REFRACTORY SOLID AND CENTRAL NERVOUS SYSTEM TUMORS Bhuvana A. Setty, Mohamed Shebl Abdelbaki, Mariko Dawn DeWire et al. · Neuro-Oncology Open access Nov 2020 0
15 EXTH-49. BXQ-350 TARGETS TO THE LYSOSOME AND KILLS GLIOBLASTOMA (GBM) CELLS VIA ACTIVATION OF APOPTOTIC CASPASES IN VITRO Nikhil Wilkins, Tim Stephens, Laura P. Felix · Neuro-Oncology Open access Nov 2020 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.